Loading...
01/10 15:55
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Financial performance showed a revenue decline and reduced margins, but cost management improved the operating loss and net loss. The Q&A reveals management's focus on U.S. growth, reimbursement normalization, and resource allocation challenges. However, lowered 2025 guidance, under-penetration, and lack of clear European strategy weigh on sentiment. Despite some positives like reduced expenses and cash position improvement, the overall sentiment remains neutral due to mixed guidance and uncertainties in execution.
Revenue $17.1 million for Q3 2025, a 13% year-over-year decline from $19.5 million in Q3 2024. The decline was primarily due to temporary reimbursement headwinds and the timing of hospital VAC reviews.
Gross Profit Margin 81.3% for Q3 2025, down from 83.7% in Q3 2024. The decline was driven by product mix, including the increasing contribution of Cohealyx and PermeaDerm to overall revenue, and other inventory-related adjustments.
Operating Expenses $23 million for Q3 2025, down 24% year-over-year from $30.2 million in Q3 2024. The reduction was due to cost reduction initiatives, including lower salaries, benefits, stock-based compensation, and reduced headcount.
Operating Loss $9.2 million for Q3 2025, a 34% improvement year-over-year from $13.8 million in Q3 2024. This improvement reflects reduced operating expenses.
Net Loss $13.2 million for Q3 2025, a 19% improvement year-over-year from $16.2 million in Q3 2024. The improvement was due to cost management and reduced operating expenses.
Cash Position $23.3 million as of September 30, 2025, up from $15.7 million at the beginning of the quarter. This increase was due to a $13.8 million private placement and improved cash management, including a 40% reduction in operating cash use quarter-over-quarter.
RECELL GO CE Mark approval: Received CE Mark approval in Europe in September, with the first patient treated in Germany.
Cohealyx: VAC submissions are underway in roughly 1/3 of target accounts, with positive clinical feedback and expected full enrollment by year-end.
PermeaDerm: Continues to perform well as a versatile biosynthetic dressing, with early results from PermeaDerm-I study being encouraging.
Market focus: Refined focus on 200 burn centers and trauma hospitals in the U.S., representing $1.3 billion of the $3.5 billion total addressable market.
Global expansion: Broadened access to RECELL technology with the first European treatment using RECELL GO.
Reimbursement clarity: All 7 MACs have published or confirmed reimbursement rates for RECELL, restoring clinician confidence and driving renewed demand.
Cost management: Reduced operating expenses by 24% year-over-year, achieving a leaner cost structure and improved cash management.
Commercial organization restructuring: Aligned structure, territories, and accountability around high-value accounts to improve focus and execution.
Forecasting improvements: Enhanced forecasting model to provide a more accurate view of future revenue.
Revenue Decline: The company reported $17 million in revenue for the quarter, below expectations and reflecting a 13% year-over-year decline. This was primarily due to reimbursement disruptions and delays in hospital Value Analysis Committee (VAC) reviews.
Reimbursement Disruption: New Category I CPT codes for RECELL procedures caused reimbursement uncertainty as regional Medicare Administrative Contractors (MACs) took time to set rates. This led to providers delaying or reducing usage of RECELL, impacting revenue.
Delayed Hospital VAC Reviews: The pace of hospital VAC reviews has been slower than anticipated, delaying the adoption and ordering of products like Cohealyx and PermeaDerm.
Commercial Organization Transition: The company is undergoing a transition in its commercial organization, which has temporarily limited near-term results and created challenges in execution and forecasting.
Cost Management Challenges: While operating expenses have been reduced, the company still faces challenges in achieving cash flow breakeven and maintaining financial sustainability.
Debt Covenant Risks: The company had to secure a waiver for its Q3 revenue covenant under the OrbiMed credit agreement and lowered its Q4 revenue covenant, indicating financial strain and potential risks in meeting future debt obligations.
Market Penetration Challenges: Despite a $3.5 billion total addressable market, the company is currently serving only 5% of its targeted $1.3 billion segment, highlighting significant under-penetration.
Product Utilization Consistency: The company faces challenges in driving consistent utilization of its products, which is critical for predictable revenue and growth.
Revenue Expectations: Full year revenue is now expected to be in the range of $70 million to $74 million, revised down from the prior guidance of $76 million to $81 million. This adjustment reflects slower-than-anticipated reimbursement normalization and measured expectations for RECELL demand and utilization through year-end.
Market Recovery and Utilization: Reimbursement clarity for RECELL has been achieved, with all 7 MACs publishing or confirming provider reimbursement rates. This is expected to progressively normalize utilization and rebuild order momentum in the coming quarters.
Growth Potential and Market Focus: The company is focusing on 200 core burn centers and trauma hospitals, representing $1.3 billion in targeted opportunity within a broader $3.5 billion U.S. market. Currently serving about 5% of this segment, providing significant runway for penetration and growth.
Product Development and Clinical Studies: Cohealyx VAC submissions are underway in roughly 1/3 of target accounts, with ordering expected to build steadily over the coming quarters. Full enrollment for the Cohealyx I study is expected by year-end, with results anticipated early next year. PermeaDerm-I study data is also expected next year.
Financial Discipline and Capital Strategy: The company is maintaining balance sheet flexibility and conserving cash while supporting operations. An update on financial outlook, including 2026 revenue and guidance, will be provided in early Q1 2026.
The selected topic was not discussed during the call.
The earnings call presents a mixed outlook. Financial performance showed a revenue decline and reduced margins, but cost management improved the operating loss and net loss. The Q&A reveals management's focus on U.S. growth, reimbursement normalization, and resource allocation challenges. However, lowered 2025 guidance, under-penetration, and lack of clear European strategy weigh on sentiment. Despite some positives like reduced expenses and cash position improvement, the overall sentiment remains neutral due to mixed guidance and uncertainties in execution.
The earnings call reveals mixed signals: strong product launches and cost savings are offset by cash decline and adoption challenges. Financial performance shows revenue growth and reduced losses, but declining gross margins and cash reserves are concerning. The Q&A section highlights adoption hurdles and cash constraints, but also potential recovery in payments. Overall, the sentiment is neutral, with no strong catalysts to suggest a significant stock price movement.
The earnings call presents a mixed outlook. While there is strong revenue growth and optimistic guidance for 2025, the company missed EPS expectations and faces regulatory and cash flow risks. The Q&A highlighted positive product developments but also uncertainties in revenue contributions. Operating expenses are high, and there is no shareholder return plan. Given these factors, the stock price reaction is likely to be neutral, as positive growth drivers are offset by financial and operational concerns.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
